914087-65-3 Usage
Molecular structure
1H-Indeno[5,4-f]quinoline-7-carboxylic acid, 3-fluorohexadecahydro-1,4a,6a-triMethyl-2-oxo-, Methyl ester, (4aR,4bS,6aS,7S,9aS,9bS,11aR)is a complex organic compound with a specific molecular structure.
Classification
It is a methyl ester of a C17 quinoline carboxylic acid derivative.
Fluorine substituent
The compound contains a fluorine atom, which can influence its chemical properties and reactivity.
Methyl groups
The compound has several methyl groups (triMethyl) attached to its structure, which can affect its stability and solubility.
Configuration
The compound has a specific configuration (4aR,4bS,6aS,7S,9aS,9bS,11aR), which determines its stereochemistry and can influence its biological activity and interactions with other molecules.
Potential applications
This chemical may have various uses in areas such as pharmaceuticals, organic synthesis, and research.
Further investigation
The exact properties and applications of 1H-Indeno[5,4-f]quinoline-7-carboxylic acid, 3-fluorohexadecahydro-1,4a,6a-triMethyl-2-oxo-, Methyl ester, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- would require additional research and study to fully understand and utilize its potential.
Check Digit Verification of cas no
The CAS Registry Mumber 914087-65-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,4,0,8 and 7 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 914087-65:
(8*9)+(7*1)+(6*4)+(5*0)+(4*8)+(3*7)+(2*6)+(1*5)=173
173 % 10 = 3
So 914087-65-3 is a valid CAS Registry Number.
914087-65-3Relevant academic research and scientific papers
Process for making fluorinated 4-azasteroid derivatives
-
Page/Page column 11, (2010/11/24)
The present invention relates to synthetic processes useful in the preparation of fluorinated 4-azasteroid derivatives that modulate androgen receptors and have application in the treatment of conditions caused by androgen deficiency or androgen receptor hyperactivity, such as osteoporosis, periodontal disease, bone fracture, frailty, erectile dysfunction, loss of libido, androgen-dependent cancers and sarcopenia. The present invention also encompasses intermediates useful in the disclosed synthetic processes and the methods of their preparation.
